These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
934 related articles for article (PubMed ID: 24339949)
1. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949 [TBL] [Abstract][Full Text] [Related]
2. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136 [TBL] [Abstract][Full Text] [Related]
3. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
4. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267 [TBL] [Abstract][Full Text] [Related]
5. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132 [TBL] [Abstract][Full Text] [Related]
6. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237 [TBL] [Abstract][Full Text] [Related]
7. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739 [TBL] [Abstract][Full Text] [Related]
8. Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. Ma BB; Mo F; Tong JH; Wong A; Wong SC; Ho WM; Wu C; Lam PW; Chan KF; Chan TS; Tsui WM; Tsang AK; Fung MN; Chan AT; To KF Asia Pac J Clin Oncol; 2015 Jun; 11(2):160-9. PubMed ID: 25865669 [TBL] [Abstract][Full Text] [Related]
9. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422 [TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623 [TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198 [TBL] [Abstract][Full Text] [Related]
12. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
13. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461 [TBL] [Abstract][Full Text] [Related]
14. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664 [TBL] [Abstract][Full Text] [Related]
16. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ciardiello F; Normanno N; Maiello E; Martinelli E; Troiani T; Pisconti S; Giuliani F; Barone C; Cartenì G; Rachiglio AM; Montesarchio V; Tonini G; Rizzi D; Cinieri S; Bordonaro R; Febbraro A; De Vita F; Orditura M; Fenizia F; Lambiase M; Rinaldi A; Tatangelo F; Botti G; Colucci G Ann Oncol; 2014 Sep; 25(9):1756-1761. PubMed ID: 24942275 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. Takahashi N; Yamada Y; Taniguchi H; Fukahori M; Sasaki Y; Shoji H; Honma Y; Iwasa S; Takashima A; Kato K; Hamaguchi T; Shimada Y BMC Res Notes; 2014 Apr; 7():271. PubMed ID: 24774510 [TBL] [Abstract][Full Text] [Related]
18. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients. Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Aranda E; Salazar R Ann Oncol; 2019 May; 30(5):796-803. PubMed ID: 30840064 [TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]